Armata Pharmaceuticals, Inc.

NYSE American ARMP

Armata Pharmaceuticals, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.07

Armata Pharmaceuticals, Inc. Revenue Per Share is USD 0.07 for the Trailing 12 Months (TTM) ending September 30, 2024, a -38.58% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Armata Pharmaceuticals, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.11, a 8.65% change year over year.
  • Armata Pharmaceuticals, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.10.
  • Armata Pharmaceuticals, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.00, a 0.00% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
NYSE American: ARMP

Armata Pharmaceuticals, Inc.

CEO Dr. Deborah L. Birx M.D.
IPO Date May 20, 1994
Location United States
Headquarters 4503 Glencoe Avenue
Employees 66
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Similar companies

ANIX

Anixa Biosciences, Inc.

USD 2.13

-2.74%

StockViz Staff

January 15, 2025

Any question? Send us an email